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Abstract
Objective: Blood monocytes are known to express endothelial-like genes during co-culture with endothelium. In this study,
the time-dependent change in the phenotype pattern of primary blood monocytes after adhering to endothelium is
reported using a novel HLA-A2 mistyped co-culture model.
Methods and Results: Freshly isolated human PBMCs were co-cultured with human umbilical vein endothelial cells or
human coronary arterial endothelial cells of converse human leukocyte antigen A2 (HLA-A2) status. This allows the tracking
of the PBMC-derived cells by HLA-A2 expression and assessment of their phenotype pattern over time. PBMCs that adhered
to the endothelium at the start of the co-culture were predominantly CD11b+ blood monocytes. After 24 to 72 hours in co-
culture, the endothelium-adherent monocytes acquired endothelial-like properties including the expression of endothelial
nitric oxide synthase, CD105, CD144 and vascular endothelial growth factor receptor 2. The expression of monocyte/
macrophage lineage antigens CD14, CD11b and CD36 were down regulated concomitantly. The adherent monocytes did
not express CD115 after 1 day of co-culture. By day 6, the monocyte-derived cells expressed vascular cell adhesion molecule
1 in response to tumour necrosis factor alpha. Up to 10% of the PBMCs adhered to the endothelium. These monocyte-
derived cells contributed up to 30% of the co-cultured cell layer and this was dose-dependent on the PBMC seeding density.
Conclusions: Human blood monocytes undergo rapid phenotype change to resemble endothelial cells after adhering to
endothelium.
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Introduction
Monocytes, a subtype of the human peripheral blood mononu-
clear cell (PBMC) population, are key cells in the host immune
system. However, recent evidence suggests an additional role of
blood monocytes in stimulating endothelial proliferation [1] as
well as acting as a potential source of endothelial-like cells [2,3,4].
Under physiological conditions, the interaction of circulating
monocytes with the endothelial layer is critical to host defence and
vascular health. To date, relatively little is known about the
physical characteristics endothelium-adherent primary blood
monocytes. In the studies reported in this paper, we utilized a
novel HLA-A2 mistyped PBMC/endothelium co-culture model to
assess phenotypic changes in human blood monocytes that adhere
to endothelium.
It has previously been reported that the gene expression pattern
in the human monocyte is radically altered after 2 hours of co-
culture with endothelium [5]. Most importantly, the up-regulated
genes in the endothelium-adherent monocytes include the
endothelium-specific E-selectin and vascular cell adhesion mole-
cule 1 (VCAM-1). One limitation of that study is the co-culture
period was short (2 hours). The monocytes were identified by
CD14 expression, which was utilized to select the monocytes out of
the co-culture for gene expression analysis. Furthermore, changes
in the expression of surface antigens on the adherent monocytes
were not documented. The aim of the current study is to evaluate
the phenotype change of endothelium-adherent monocyte in the
longer term using a novel HLA-A2 mistyped PBMC/endothelium
adherent co-culture model. PBMCs were obtained from either
HLA-A2 positive (HLA-A2+) or HLA-A2 negative (HLA-A22)
donors and then co-cultured with human umbilical vein endothe-
lial cells (HUVECs) or human coronary arterial endothelial cells
(HCAECs) of the converse HLA-A2 status. This arrangement
allowed the PBMC-derived cells to be tracked by their HLA-A2
expression without using surface antigens such as CD14, which
may be altered during co-culture. HLA class I mistyping is an
accepted method for discriminating and quantifying allogeneic cell
populations in mixed leukocyte culture [6]. HLA-A2 mistyping has
also been used to reliably track the in vivo fate of platelets after
transfusion [7]. HLA-A2+ individuals represent 35–50% of the
general population [8] and can be readily identified. This
approach allows us to identify PBMC subtypes that adhered to
the endothelium and track their subsequent phenotype change
without having to label the cells with reagents that may interfere
with their biology.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37091In this paper, we reported that the PBMC subtype that adhered
to the endothelium is the CD11b+ monocyte and these adherent
cells underwent a time-dependent phenotype change to resemble
endothelial cells.
Methods
Ethics Statement
PBMCs were obtained from healthy human volunteers with
written consent in accordance with the Declaration of Helsinki.
This is classified as negligible risk to the donors and therefore do
not require ethical approval according to section 5.1.22 of the
Australian National Statement on Ethical Conduct in Human
Research (2007).
Preparation of the Endothelium
HUVECs were obtained from umbilical cords provided by the
Royal Prince Alfred Hospital in Sydney. Each batch of HUVECs
were isolated from a single umbilical cord using an established
collagenase digestion technique [9] and was maintained in M199
culture medium (Invitrogen, Australia) supplemented with 10%
foetal bovine serum (FBS, Invitrogen, Australia). HCAECs were
obtained from Cell Applications, Inc (USA) and were maintained
in Meso Endo Cell Growth Medium (Cell Applications, Inc. USA)
before the start of the co-culture experiments. The HUVECs and
HCAECs were screened for HLA-A2 status by immunofluores-
cence. Briefly, the cells were treated with trypsin, incubated for
45 min at 4uC with either an Alexa FluorH 488 (AF488)
conjugated mouse anti-human HLA-A2 monoclonal antibody
(Serotec) or an AF488 conjugated mouse isotype control antibody
(Serotec) and analysed with one-colour flow cytometry. HUVECs
(passage 2, density from 0.1 to 0.3610
6 cells/well) were seeded
onto 6 well (9.6 cm
2/well) culture plates (Bectin Dickinson
Labware) 24–48 h before the co-culture experiments.
PBMC/Endothelium co-culture
Healthy human volunteers were screened for HLA-A2 status
using direct immunofluorescence techniques as described above.
Briefly, venous blood was collected from the donors into sterile
EDTA-Na2 tubes, which was then diluted 1:1 with phosphate
buffered saline (PBS) and centrifuged at 200 g for 15 min to
remove the platelet-rich supernatant. The PBMCs were isolated
by density gradient centrifugation (Lymphoprep
TM) and washed in
PBS at 1:1 dilution. The PBMCs were incubated with either an
AF488 conjugated mouse anti-human HLA-A2 monoclonal
antibody (Serotec) or an AF488 conjugated mouse isotype control
antibody (Serotec) and analysed with one-colour flow cytometry.
For the co-culture experiments, HLA-A2+ PBMCs were added
immediately after isolation at densities ranging from 0.25 to 2610
6
cells/well onto HLA-A22 HUVEC layers. Reverse HLA-A2
mistyping co-culture experiments with HLA-A22 PBMCs and
HLA-A2+ HUVECs were also performed. The PBMCs and
HUVECs were co-incubated at 37uC for 2 h in M199 supple-
mented with either 10% FBS or heat-inactivated human serum
(HIHS), after which the non-adherent PBMCs were removed by
washing. The cell layers were analysed by three-colour flow
cytometry at serial time points between day 0 and day 6 of co-
culture. For each experiment, PBMCs from a single donor were
co-cultured with HUVECs from a single source and the medium
was supplemented with a single batch of serum. To assess VCAM-
1 expression, the co-cultures were stimulated for 24 h with TNF-a
(10 ng/ml) on day 5 of co-culture. Co-culture experiments were
also done with PBMCs and HCAECs using the same techniques
and under the same culture conditions for comparison.
Immunofluorescence and flow cytometry
Three-colour direct immunofluorescence flow cytometry (Cy-
tomics FC500, Beckman Coulter) was used to characterize and
quantify the HLA-A2+ cells. The co-culture cell layers were
dissociated with either trypsin or by gentle scraping. Total cell
counts were estimated using a manual haemocytometer. For
detection of surface antigens, the detached cells were incubated for
45 minutes at 4uC with AF488, R-phycoerythrin (R-PE) and PE-
Cy5 conjugated primary antibodies (1:50 or 1:100). For the
detection of intracellular antigens, the cells were fixed and
permeabilized using the Fix & PermH kit (Invitrogen). The
AF488 conjugated monoclonal mouse anti-human HLA-A2
antibody (Serotec) was used to detect HLA-A2 expression. R-
PE-conjugated monoclonal antibodies included mouse anti-
human CD31 (BD Biosciences), eNOS (BD Biosciences), CD105
(Serotec), CD144 (Santa Cruz and R&D Systems), CD14 (BD
Biosciences), CD11b (BD Biosciences), CD16 (BD Biosciences),
CD36 (BD Biosciences), CD115 (R&D Systems), VEGFR2 (R&D
Systems), CD34 (BD Biosciences), ICAM-1 (BD Biosciences) and
VCAM-1 (BD Biosciences). The PE-Cy5-conjugated CD11b (BD
Biosciences) antibody was used for 3-colour flow cytometry
analysis. AF488, R-PE and PE-Cy5 conjugated mouse isotype
control antibodies as recommended by the manufacturers were
used to exclude non-specific binding. HUVECs that had not been
subjected to co-culture with PBMCs were incubated with the
HLA-A2 AF488 antibody as cell controls. Fluorescence images
were acquired with a Olympus IX71 microscope using the
manufacturer’s software.
Statistical analysis
Data sets were compared with a two-tailed unpaired Student’s t-
test (Microsoft Excel) and P,0.05 was considered statistically
significant.
Results
Effects of co-culture duration on the phenotype of
endothelial-adherent monocytes
After 2 h of co-incubating HLA-A2+ PBMCs with HLA-A22
HUVECs, the endothelium-adherent HLA-A2+ cells were
CD342/CD14+/CD11b+/CD162 (Figure 1A to D) and were
predominantly CD1052/CD1442 (Figure 1E and F). Thus the
phenotype of the endothelium-adherent PBMCs was consistent
with that of blood monocytes.
After 24 h of co-culture, the expression of CD14 and CD11b on
the HLA-A2+ adherent monocytes was markedly down-regulated
(Figures 2A and B). At the 2 h time point, 63.266.6% of the HLA-
A2+ cells expressed CD14; after 24 h of co-culture only
35.8622.5% of the HLA-A2+ cells expressed CD14 (P=0.02).
The percentage of the HLA-A2+ cells that expressed CD14
remained at 32.6620.1 for up to 5 days of co-culturing (Figure 2C).
Similarly, 82.266.6% of the HLA-A2+ cells expressed CD11b at
the 2 h time point but this was reduced to 56.9616.2% by 24 h
(P,0.01). After 2 to 3 days of co-culture, the percentage of HLA-
A2+ cells that expressed CD11b was further reduced to
39.2610.5% (P=0.05 compared to 24 h) (Figure 2D).
Coinciding with this down-regulation of monocyte antigens, the
endothelium-adherent HLA-A2+ monocytes began to express the
endothelial antigens CD105 (Figure 3A) and CD144 (Figure 3B).
At 2 h, only 10.866.7% of the HLA-A2+ cells expressed CD105
(Figure 3C). By 24–48 h, 61.6617% of the HLA-A2+ cells
expressed CD105 (P,0.01). This value remained constant up to
Day 6 of co-culture (Figure 3C). At the 2 h time point, only
5.164% of the HLA-A2+ cells expressed CD144 (Figure 3D),
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(P,0.01). After 3 to 6 days in co-culture, CD144 expression by the
HLA-A2+ cells was further increased to 83.9610.3% (P,0.01
compared to the 24–48 h time point) (Figure 3D). Three-colour
flow cytometry analysis of the simultaneous staining for HLA-A2,
CD105 and CD11b showed a clear shift of the HLA-A2+/
CD11b+/CD1052 cells into HLA-A2+/CD11b2/CD105+ cells
between day 1 (Figure 4A) and day 2 (Figure 4B) of co-culture.
This is consistent with simultaneous down regulation of CD11b
and up regulation of CD105 within the same cell population
during the 24 hour period.
In addition to the changes in the endothelial and monocytic
antigens, the monocyte-derived cells increased in size and
granularity from 2 h (Figure 4C) to day 2 (Figure 4D) of co-
culture as demonstrated by the forward scatter/side scatter dot
plots.
The adherent monocytes did not express the M-CSF receptor
CD115 after 1 day in co-culture and remained CD342 after 2
days in co-culture (data not shown).
To exclude the possibility that the HLA-A2 antigen may be
transferred from microparticles derived from contaminating HLA-
A2+ platelet or monocytes to the HLA-A22 HUVECs, the HLA-
A2 mistyping was reversed (HLA-A22 PBMCs with HLA-A2+
HUVECs) and analysed on day 2 of co-culture. This confirmed
that 33.768.9% of the HLA-A22 adherent monocytes expressed
CD105 and that expression of CD14 (9.461.2% of the adherent
monocytes) and CD11b (18.468.6% of the adherent monocytes)
was low.
Figure 1. Endothelial adherence of blood monocytes. PBMCs were isolated from HLA-A2+ donors and incubated with HLA-A22 HUVECs
(1610
6 cells/well) for 2 h, after which the non-adherent PBMCs were removed by washing. The co-cultured cell layers were immediately analysed
with dual-colour flow cytometry for HLA-A2 and (A) CD34, (B) CD14, (C) CD11b, (D) CD16, (E) CD105 and (F) CD144 expression. Representative plots
from 4–6 individual experiments are shown. (G) Two parameters dot plot showing typical isotype controls.
doi:10.1371/journal.pone.0037091.g001
Figure 2. Down-regulation of CD14 and CD11b expression in the endothelium-adherent monocytes during co-culture. HLA-A2+
PBMCs (1610
6 cells/well) were incubated for 2 h (Day 0) with HLA-A22 HUVECs, after which the non-adherent cells were removed by washing. The
cell layers were assessed by dual-colour flow cytometry for HLA-A2 and (A) CD14 expression on Day 1 and (B) CD11b expression on Day 3 of co-
culture. These are representative plots from 4–7 individual experiments. The reduction in CD14 expression from Day 0 to Day 5 (C) and CD11b
expression from Day 0 to Day 3 (D) is also shown.
doi:10.1371/journal.pone.0037091.g002
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endothelium-adherent monocytes
To determine whether the phenotype changes to the endothe-
lium-adherent monocytes were accompanied by expression of
molecules that are required for endothelial function, VEGFR2,
endothelial cell adhesion molecules and the class B scavenger
receptor, CD36 levels were quantified. After 24 h of co-culture,
the HLA-A2+ adherent monocytes were still predominantly
VEGFR2- (Figure 5A). However, by 48 h, 43.3% of the adherent
monocytes expressed VEGFR2 (Figure 5B). In the absence of
stimulation by TNF-a, VCAM-1 was not expressed by the HLA-
A2+ monocytes either at 2 h (result not shown) or at Day 5 of co-
culture (Figure 5C). After 5 days of co-culture, activation with
TNF-a induced VCAM-1 expression in 45.6% of the HLA-A2+
cells (Figure 5D). At 2 h, CD36 was expressed by the majority of
the endothelium-adherent monocytes (Figure 5E), but after 24 h,
expression of this receptor by the adherent monocytes was reduced
to only 10% (Figure 5F). All the endothelial-adherent HLA-A2+
cells expressed CD31 (Figure 5G) and ICAM-1 (Figure 5H) at 2 h
of co-culture consistent with constitutive expression of these
antigens. This was maintained for up to 4 days in co-culture (result
not shown).
Endothelial nitric oxide synthase expression
We also investigated the expression of endothelial nitric oxide
synthase (eNOS) by the endothelium-adherent monocytes in co-
culture, which is a critical indicator of endothelial functionality.
Freshly isolated PBMCs did not express eNOS prior to co-culture
(Figure 6A). In contrast, 30.5% of the HLA-A2+ cells expressed
eNOS after 24 h in co-culture (Figure 6B). Three-colour flow
cytometry with simultaneous staining for HLA-A2, CD11b and
eNOS showed that the majority of the HLA-A2+/eNOS+ cells
were CD11b2 (Figure 6C). Expression of eNOS was visualized
with fluorescence microscopy after 2 h and 24 h of co-culture. At
2 h, the adherent HLA-A2+ cells (green) were small round cells
that were eNOS2 (Figure 6D). After 24 h, these cells increased in
size and became eNOS+ (red, Figure 6E), consistent with the flow
cytometry analysis.
Collectively, these phenotype changes to the HLA-A2+ cells in
combination with the increase in size and granularity provide
compelling evidence that the endothelial-adherent monocytes
acquired endothelial-like properties and we termed this monocyte-
derived endothelial-like cells (M-ELCs).
The use of either FBS or HIHS to enrich the culture medium
had no effect on the phenotype changes of these adherent
monocytes (result not shown).
PBMC/HCAEC Co-Culture
To assess whether the changes of the blood monocytes in co-
culture with endothelium are specific to HUVECs, further co-
culture experiments were done using HCAECs. The phenotype of
the PBMCs that adhered to the HCAEC by 2 h of co-culture was
Figure 3. Increased expression of CD105 and CD144 in the endothelium-adherent monocytes during co-culture. HLA-A2+ PBMCs
(1610
6 cells/well) were incubated for 2 h (Day 0) with HLA-A22 HUVECs, after which the non-adherent cells were removed by washing. The cell
layers were maintained in co-culture up to Day 6, then assessed by dual-colour flow cytometry for HLA-A2 and (A) CD105 and (B) CD144 expression
on Day 3 of co-culture. Representative plots from 4–7 individual experiments are shown. The increase in CD105 from Day 0 to Day 6 (C) and CD144
expression from Day 0 to Day 6 (D) is also shown.
doi:10.1371/journal.pone.0037091.g003
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shown). The phenotype changes by Day 2 of co-culture were also
identical to the PBMC/HUVEC co-cultures with acquisition of
CD105 (Figure 7A), eNOS (Figure 7B) and VEGFR2 (Figure 7C).
CD14 and CD11b were down regulated (data not shown). Hence,
the phenotype changes of the endothelium-adherent blood
monocytes were not specific to the use of HUVECs.
Quantification of M-ELC generation
When HLA-A2+ PBMCs were seeded at a dose of 1–1.5610
6
cells/well onto confluent HLA-A22 HUVEC layers, 9–30% of
the total co-culture cell layer was HLA-A2+ after 2 h of co-culture.
The number of PBMCs that adhered to the HUVECs represented
4–10% of the PBMC population that was initially seeded. The
percentage of HLA-A2+ cells in the co-culture cell population
remained constant for up to 3 days.
The effect of varying the seeding density of PBMCs on the
percentages of the M-ELCs in the total co-culture population was
evaluated using low (0.25610
6), intermediate (0.5610
6) and high
(1610
6) numbers of PBMCs/well. For any given experiment
described in this section, a single batch of HLA-A22 HUVECs
was seeded at a density of 0.15610
6 cells/well. The HLA-A2+
PBMCs were taken from a single donor. Non-adherent PBMCs
were removed by washing after 2 h and the incubation continued
for 24 h. When added at a seeding density of 0.25610
6 cells/well,
HLA-A2+ cells accounted for 3.160.4% of the total cells in the co-
culture layer after 24 h of co-culture. The proportion of HLA-2+
cells in the co-culture layer after 24 h of incubation increased to
6.360.2% when seeded at a density of 0.5610
6 PBMCs/well and
increased further to 12.660.2% when seeded at a density of
1610
6 PBMCs/well (Figure 8). These percentages and the total
cell counts were used to establish that the low, intermediate and
high dose PBMC groups contained 20,000, 50,000 and 150,000
HLA-A2+ cells per well, respectively. Thus, the number of M-
ELC after 24 h of culture was proportional to the PBMC seeding
density and represented 7.6% to 15% of the starting PBMC
population. Reversing the HLA-A2 mistyping with HLA-A22
PBMC and HLA-A2+ HUVEC revealed a similar PBMC dose-
response, with 5.560.4% M-ELCs in the 0.25610
6 PBMC/well
group, 8.160.6% in the 0.5610
6 PBMC/well group and
14.861.2% in the 1.0610
6 PBMC/well group (Figure 8).
The effect of varying the seeding density of the HUVECs on the
proportion of M-ELC was evaluated by plating the HLA-A22
HUVECs at low (0.1610
6 cells/well), intermediated (0.2610
6
cells/well) and high (0.3610
6 cells/well) density 24 h before
adding the HLA-A2+ PBMCs. The PBMCs were added to the
HUVECs at 1610
6 cells/well in all groups. Non-adherent PBMCs
were washed off after 2 h and the co-culture was maintained for 2
days. Under these conditions the percentage of HLA-A2+ cells in
the low, medium and high HUVECs seeding densities remained
remarkably stable at 14.761.3%. The total co-cultured cell counts
were 0.17610
6, 0.35610
6 and 0.57610
6 cells/well in the low,
medium and high HUVEC seeding densities, respectively. This
Figure 4. Phenotype change from HLA-A2+/CD11b+/CD1052 to HLA-A2+/CD11b2/CD105+ on endothelium-adherent blood
monocyte-derived cells with increase in size and granularity during co-culture. HLA-A2+ PBMCs (1610
6 cells/well) were incubated for 2 h
(Day 0) with HLA-A22 HUVECs, after which the non-adherent cells were removed by washing. The cell layers were analysed by three-colour flow
cytometry staining for HLA-A2, CD11b and CD105 on (A) Day 1 and (B) Day 2. These plots were gated for HLA-A2+ cells. Forward scatter/side scatter
dot plots gated for HLA-A2+ cells on Day 0 (C) and Day 2 (D) was shown. These are representative of 2 individual experiments.
doi:10.1371/journal.pone.0037091.g004
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endothelium-adherent monocytes in co-culture. HLA-A2+ PBMCs (1610
6 cells/well) were incubated for 2 h (Day 0) with HLA-A22 HUVEC, after
which the non-adherent cells were removed by washing. The cell layers were analysed by dual-colour flow cytometry for HLA-A2 and VEGFR2
expression on Day 1 (A) and Day 2 (B) of co-culture, VCAM-1 expression in the absence of TNF-a on Day 6 of co-culture (C), VCAM-1 expression on Day
6 of co-culture after 24 hours of stimulation with TNF-a (10 ng/ml) (D), CD36 expression on Day 0 (E) and Day 1 (F) of co-culture, as well as CD31 (G)
and ICAM-1 (H) expression on Day 0. Representative plots from 2–5 individual experiments are shown.
doi:10.1371/journal.pone.0037091.g005
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independent of HUVEC density.
Discussion
The key finding in this study is that the majority of human
blood monocytes that adhered to the endothelial layer underwent
Figure 6. Expression of eNOS in endothelium-adherent monocytes in co-culture. Dual-colour flow cytometry analysis of CD14 and eNOS
expression on freshly-isolated PBMCs before co-culture (representative of 2 individual experiments) is shown (A). HLA-A2+ PBMCs (1610
6 cells/well)
were incubated for 2 h with HLA-A22 HUVECs, after which the non-adherent PBMCs were removed by washing. (B) Shows the flow cytometry
analysis of the cell layers for HLA-A2 and eNOS expression on Day 1 of co-culture (representative of 3 individual experiments). (C) Shows the 2
parameters dot plot from 3-colour flow cytometry analysis on Day 1 of co-culture staining for HLA-A2, CD11b and eNOS. This plot is gated for HLA-
A2+ cells (representative of 2 individual experiments). Immunofluorescent micrographs (660 original magnification) showing endothelial-adherent
HLA-A2+ cells (green) and eNOS expression (red) on Day 0 (D) and Day 1 (E) of co-culture (representative of 2 individual experiments). The nuclei were
stained with DAPI. Scale bar=20 mm.
doi:10.1371/journal.pone.0037091.g006
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distinct from the typical monocyte/macrophage lineage.
Human blood monocytes express endothelial antigens under
angiogenic conditions [2,3,4] and blood monocytes in direct
contact with endothelium express endothelium-specific genes [5].
Furthermore, human monocytes/macrophages cultured for 10–14
days ex vivo are known to acquire endothelial-like morphology and
also expressed endothelial-specific antigens when added to
HUVEC after a further culture period of 7 days [10]. The
current study is the first to show that when primary blood
monocytes adhere to endothelial cells, they change from a typical
monocyte phenotype to a phenotype resembling that of endothe-
lial cells.
Antigens expressed by endothelium-adherent monocytes dif-
fered markedly from that of typical blood monocytes. In contrast
to typical blood monocytes, endothelium-adherent monocytes
expressed a number of endothelial antigens, including CD105,
CD144, VEGFR2, VCAM-1 and eNOS. CD105 is a component
of the transforming growth factor-beta receptor system that is
typically expressed by activated endothelium [11]. CD144 (VE-
cadherin) is a component of the highly specific endothelial
adherent junction [12,13,14]. VEGFR2 is a receptor of vascular
endothelial growth factor that is specific to endothelium.
Furthermore, fresh, non-adherent monocytes do not express
VCAM-1, either in the basal or activated state. In the current
co-culture model, we found that activation by TNF-a induced
VCAM-1 expression in the endothelium-adherent monocytes,
which is a well-documented feature of endothelial cells [15]. In
addition, the adherent (but not fresh) monocytes expressed eNOS,
an intracellular enzyme that plays a key role in regulating the
vasomotor tone that defines endothelial functionality.
Expression of the monocyte integrin CD11b is normally
increased in monocytes during cell activation and macrophage
differentiation [16,17,18]. However, in the endothelium-adherent
monocytes, CD11b was down regulated, providing further
evidence of a shift away from the monocyte/macrophage lineage.
The scavenger receptor CD36 is another monocyte/phagocyte
antigen [19] that contributes to the uptake of modified LDLs and
is fundamental for monocyte-macrophage differentiation [20,21].
We found that CD36 expression in endothelium-adherent
monocytes was down regulated after 24 hours of co-culture,
providing yet another indication that these cells had shifted away
from their phagocytic lineage. Collectively, the acquisition of
endothelial antigens combining with the loss of monocytic/
phagocytic antigens strongly indicated that the endothelium-
adherent monocytes had differentiated into cells with the
phenotype and functionality of typical endothelial cells. The
current findings highlight the potential of blood monocyte as a
substantial source of endothelial cell replacement.
Platelet or monocyte-derived microparticles are unlikely to be
involved in this process as the reverse HLA-A2 mistyping exclude
the transfer of HLA-A2 via microparticles. Furthermore, platelet
microparticles promote macrophage differentiation of monocytes
[22], which is opposite to our observations. The mechanism by
which contact with the endothelium results in the differentiation of
blood monocytes into endothelial-like cells remains to be
determined.
In conclusion, a substantial proportion of circulating monocytes
has the potential to rapidly transform into endothelial-like cells
after adhering to pre-existing endothelium. This process may be
beneficial in promoting vascular repair and improving vascular
health.
Figure 7. Expression of endothelial antigens in endothelium-
adherent monocytes in co-culture with HCAECs. HLA-A2+ PBMCs
(1610
6 cells/well) were incubated for 2 h (Day 0) with HLA-A22
HCAECs, after which the non-adherent cells were removed by washing.
The cell layers were analysed by dual-colour flow cytometry for HLA-A2
and (A) CD105, (B) eNOS and (C) VEGFR2 expression on Day 2 of co-
culture.
doi:10.1371/journal.pone.0037091.g007
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